Highest-materiality recent filing
Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA
Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
Aptose delays closing of Hanmi arrangement; targets May 2026 for completion
Closing delayed as Korean regulatory approvals remain in progress; parties do not anticipate prevention.
Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M
Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).
Aptose shareholders approve continuance to Alberta and Hanmi acquisition arrangement
Continuance from CBCA to Alberta approved with 92.42% votes in favor.
Glass Lewis backs Aptose's plan for Hanmi acquisition; vote deadline March 27
Glass Lewis recommends shareholders vote FOR the arrangement with Hanmi and the continuance to ABCA.
ISS recommends Aptose shareholders vote FOR Hanmi arrangement at C$2.41/share
ISS recommends voting FOR the arrangement with Hanmi Pharmaceutical and the continuance to ABCA.
Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan
Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML
90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.
Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash
Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP
Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.
Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses
Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.
Aptose tuspetinib combo achieves 100% CR/CRh at higher doses in newly diagnosed AML trial
TUS+VEN+AZA achieved 100% CR/CRh (6/6) at 80mg and 120mg doses, exceeding 66% expected from VEN+AZA alone.
Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study
Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.
Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial
100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).
Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg
Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.
Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi
CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.
Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial
Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.
Aptose defers interest payment on Hanmi loan to December 31, 2025
Interest for Dec 21, 2024–Mar 31, 2025, originally due June 27, 2025, deferred to Dec 31, 2025.
Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development
Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.
CEO William Rice provides non-interest bearing, unsecured short-term cash advance to support payroll and obligations.
All 7 director nominees re-elected with ≥97.69% votes for.
On June 16, 2025, Carol Ashe notified the Board of Directors (the “Board”) of Aptose Biosciences Inc. (the “Company”) of her intention to resign from her role as a member of the Board effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material